Levofloxacin Hydrochloride Tablets

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has good antibacterial effects on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococcus, and Gram-positive bacteria, as well as Legionella, Mycoplasma, and Chlamydia, but has poor effects on anaerobic bacteria and enterococci.

The main ingredient of this product is levofloxacin, and its chemical name is: (S)-(-)-9-fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridinephenyl[1,2,3-de]-[1,4]benzoxazine-6-carboxylic acid hydrochloride monohydrate. [Molecular formula] C18H20FN3O4 [Molecular weight] 415.85

This product is a white film-coated tablet, which appears off-white or light yellow after removing the film.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis complicated with infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal) inflammation, subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections

Oral administration: 0.1-0.2g (1-2 tablets) per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, lack of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms, as well as rash, itching and other symptoms may occur. Transient liver function abnormalities may also occur, such as increased serum aminotransferase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: It is contraindicated for patients under 18 years old. Precautions for pregnancy and lactation: It is contraindicated for pregnant and lactating women. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

Drug interactions: When this product is used simultaneously with antacids containing magnesium or aluminum, sucralfate, metal cations (such as iron), and zinc-containing multivitamin preparations, it will interfere with the absorption of this product by the gastrointestinal tract, causing the concentration of this drug in various systems to be significantly reduced. Therefore, the time of taking the above drugs should be at least 2 hours before or after using this product. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. When used simultaneously with non-steroidal anti-inflammatory drugs, there is a possibility of convulsion. When used simultaneously with oral hypoglycemic drugs, it may cause blood sugar disorders, including hyperglycemia and hypoglycemia. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Sealed and light-proof.

Calculated as C18H20FN304 0.1g

24 months

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

• Founded in:

  1997-04-28

• Address:

  No. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone

• Tax NO.:

  9132070070404786XB

• Registered Funds:

  6,379,002,274 yuan

• Website:

  Log in to view

• Email:

  Log in to view